Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients (vol 5, pg 312, 2017)

被引：3
|
作者：
de Velasco, G.
Je, Y.
Bosse, D.
Awad, M. M.
Ott, P. A.
Moreira, R. B.
Schutz, F.
Bellmunt, J.
Sonpavde, G. P.
Hodi, F. S.
Choueiri, T. K.
机构：
来源：
CANCER IMMUNOLOGY RESEARCH | 2018年 / 6卷 / 04期
关键词：
D O I：
10.1158/2326-6066.CIR-18-0078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：498 / 499
页数：2
相关论文
共 50 条
  • [1] Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
    De Velasco, Guillermo
    Je, Youjin
    Bosse, Dominick
    Awad, Mark M.
    Ott, Patrick A.
    Moreira, Raphael B.
    Schutz, Fabio
    Bellmunt, Joaquim
    Sonpavde, Guru P.
    Hodi, F. Stephen
    Choueiri, Toni K.
    CANCER IMMUNOLOGY RESEARCH, 2017, 5 (04) : 312 - 318
  • [2] Meta-Analysis of Efficacy From CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
    Xu, Li
    Yan, Xin
    Ding, Weiyue
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [3] Treatment-related adverse events of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in clinical trials: a meta-analysis
    Mi, Ze
    Zhang, Yunshu
    Feng, Zhichao
    Liu, Jiahao
    Wu, Jianmin
    Tan, Hongpei
    Ma, Xiaoqian
    Liu, Zhenguo
    Rong, Pengfei
    ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2022, 50 (01) : 301 - 309
  • [4] Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials
    Sonpavde, Guru P.
    Grivas, Petros
    Lin, Yushun
    Hennessy, Daniel
    Hunt, Jay D.
    FUTURE ONCOLOGY, 2021, 17 (19) : 2545 - 2558
  • [5] Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis
    Jin, Chunhui
    Zhu, Xiaodan
    Huang, Xiaona
    Gong, Tingjie
    Wei, Zhipeng
    You, Jianliang
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 11 (03) : 203 - 212
  • [6] Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
    Feng, Yuqian
    Jin, Huimin
    Guo, Kaibo
    Xiang, Yuying
    Zhang, Yiting
    Du, Wurong
    Shen, Minhe
    Ruan, Shanming
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [7] Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials (vol 17, pg 2545, 2021)
    Sonpavde, G. P.
    Grivas, P.
    Lin, Y.
    Hennessy, D.
    Hunt, J. D.
    FUTURE ONCOLOGY, 2023, 19 (21) : 1513 - 1513
  • [8] Immune-Related Adverse Events (irAEs) Following CTLA-4 and PD-1/PD-L1 Blockade in Advanced Melanoma: A Comprehensive Rapid Autopsy Study
    Bavi, Prashant
    Kiehl, Rasmus
    Adeyi, Oyedele
    Mete, Ozgur
    Avila-Casado, Carmen
    Sharifzad, Hamidreza
    Joshua, Anthony
    Butany, Jagdish
    Roehrl, Michael H.
    LABORATORY INVESTIGATION, 2016, 96 : 4A - 4A
  • [9] Immune-Related Adverse Events (irAEs) Following CTLA-4 and PD-1/PD-L1 Blockade in Advanced Melanoma: A Comprehensive Rapid Autopsy Study
    Bavi, Prashant
    Kiehl, Rasmus
    Adeyi, Oyedele
    Mete, Ozgur
    Avila-Casado, Carmen
    Sharifzad, Hamidreza
    Joshua, Anthony
    Butany, Jagdish
    Roehrl, Michael H.
    MODERN PATHOLOGY, 2016, 29 : 4A - 4A
  • [10] Comprehensive analysis of five key immune related adverse events (irAE) from immune checkpoint blockers (ICB) CTLA-4 and PD-1 inhibitors in cancer patients
    de Velasco, Guillermo
    Je, Youjin
    Awad, Mark M.
    Ott, Patrick Alexander
    Schutz, Fabio Augusto Barros
    Bellmunt, Joaquim
    Sonpavde, Guru
    Hodi, F. Stephen
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345